FeesSafety
Pluang+

Monte Rosa Therapeutics seen as undervalued after related drug trial failures impact stock price

Market News
17 Nov 2026, 16:03 WIB
Seeking Alpha
View Source
Bearish
Monte Rosa Therapeutics seen as undervalued after related drug trial failures impact stock price

Monte Rosa Therapeutics' stock price dropped following the failure of Novo Nordisk's drug ziltivekimab in a cardiovascular trial, which negatively affected market perception of Monte Rosa's NEK7 degrader MRT-8102 despite targeting a different condition. The company’s gout treatment, GEMINI-1, offers a nearer-term value opportunity with initial clinical data expected in the second half of 2027. Monte Rosa’s enterprise value is about $220 million, significantly lower than comparable deals like Lilly's $1.2 billion acquisition of Ventyx, despite having a promising pipeline and a partnership with Novartis. While milestone payments from Novartis provide financial runway into 2029, risks remain from trial execution, competition, and the fact that biomarkers do not guarantee clinical outcomes.

Monte Rosa Therapeutics faces market challenges as seen in the broader health sector on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 17, 2026 21:01 WIB: Out of 150 priced health-sector US stocks, 40 rose and 103 fell today. Notable movers include SYRE (Spyre Therapeutics Inc.) down 12.52% at USD 86.93 with a typical hold time of 6 days, NUWE (Nuwellis Inc) down 4.76% at USD 4.40 with a typical hold time of 33 days, and NTRA (Natera Inc.) up 4.14% at USD 300.42 with 100% buy order activity and a typical hold time of 10 days.

More News

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene Inc. and City of Hope have started a Phase 1 clinical trial testing a new combination therapy for metastatic colorectal cancer patients resistant to standard treatments. The trial evaluates two experimental drugs, ivonescimab and muzastotug (...

Others
Bullish
1 hour ago
Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank announced three key leadership appointments to strengthen its Commercial Banking division. Edward Galan will lead Middle Market Lending, Dawn Scocco will manage portfolio and credit risk, and John Maio will head Treasury Management Ser...

Market News
Bullish
1 hour ago
RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand Company Ltd. has released its first mobile game, Palazzo Chronicles: Match 3, on the Google Play Store. The free-to-play match-3 puzzle game features over 270 levels where players restore a royal palace set in Risorgimento Italy. This launch...

Others
Bullish
1 hour ago
Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan, with over 25 years in financial technology including roles at Goldman Sachs and Coinbase, has joined Dune as Director of Engineering. He will lead the engineering efforts behind Dune Market Data Feeds, which provide real-time trade and liq...

Others
Bullish
1 hour ago
BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock, Inc. has increased its total voting rights in ICG PLC to 5.16% as of November 13, 2026, up from 5.17% previously reported. This includes 5.08% voting rights attached to shares and 0.08% through financial instruments. The notification was o...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App